Alembic Pharmaceuticals Limited

Sümbol: APLLTD.NS

NSE

990.3

INR

Turuhind täna

  • 33.3489

    P/E suhe

  • 0.6374

    PEG suhe

  • 194.66B

    MRK Cap

  • 0.01%

    DIV tootlus

Alembic Pharmaceuticals Limited (APLLTD-NS) Finantsaruanded

Diagrammil näete Alembic Pharmaceuticals Limited (APLLTD.NS) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Bilanss

Sukeldudes Alembic Pharmaceuticals Limited fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010

balance-sheet.row.cash-and-short-term-investments

0921.2610.92850.3
718.4
1990.7
959.3
1530.8
4508.3
268.3
239.6
161.1
470.8
62.9

balance-sheet.row.short-term-investments

0166.4316.21869.7
0
0
121.8
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

011291.111900.18067.3
12033.6
6152.6
7268.1
5352.4
4781.5
0
0
0
0
0

balance-sheet.row.inventory

014752.71609714861.5
11875.3
9672.6
7339.3
6327.5
5775.8
3827.7
3107.8
2668.3
2587.4
2192.3

balance-sheet.row.other-current-assets

02135.2-0.1-0.1
0.2
1761.4
2680.8
-0.1
0
4811.4
4204.4
3492.2
3817.3
3163.7

balance-sheet.row.total-current-assets

029100.228607.925779
24627.5
19577.3
18247.5
13210.6
15065.6
8907.4
7551.7
6321.6
6875.5
5418.9

balance-sheet.row.property-plant-equipment-net

029997.339472.636480.3
30990.1
24399.9
18377.6
11686.8
8237.5
5947.3
4176.3
3764.8
3260.6
2985

balance-sheet.row.goodwill

0000
0
36
37.7
0
435.6
352.8
0
0
0
0

balance-sheet.row.intangible-assets

001548.23229.5
2990.2
2662.7
1619.7
270
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

001548.23229.5
2990.2
2698.7
1657.4
270
435.6
352.8
0
0
0
0

balance-sheet.row.long-term-investments

0963.31184493.1
176.2
487.6
294.6
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

01230.158.81108
1106.6
148.5
121.8
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0537.4348.8-0.1
-0.1
467.3
711.4
1699.4
855.1
1204.2
450
391.8
382.9
32.6

balance-sheet.row.total-non-current-assets

032728.142612.441310.8
35263
28202
21162.8
13656.2
9528.2
7504.3
4626.3
4156.6
3643.5
3017.6

balance-sheet.row.other-assets

0000
0
-1.7
0.2
0
0
0
0
0
0
0

balance-sheet.row.total-assets

061828.371220.367089.8
59890.5
47777.6
39410.5
26866.8
24593.8
16411.7
12178
10478.2
10519
8436.5

balance-sheet.row.account-payables

06798.17063.96687.7
6259.3
50.9
2
11.5
8.8
9.6
8.8
5.6
2091.5
0

balance-sheet.row.short-term-debt

06527.96449.73121.8
8704
6291.3
2077.8
885.2
1564.2
2447
571.8
1162.6
1394.6
0

balance-sheet.row.tax-payables

00021.5
0
36.1
0
97.9
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0692.3721.42714.3
9602.9
4993
5000
0
0
188
522.2
705.3
948.6
3279.1

Deferred Revenue Non Current

0-831.4-1976.9855.2
745.1
520.3
616.6
0
0
93.6
66.8
60.6
53.9
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0855.4-0.10.2
418.9
213.5
9155.1
-0.2
0.7
0.9
4.9
4.8
1505.7
2136.3

balance-sheet.row.total-non-current-liabilities

01754.31679.53611.7
10470
5701
5971.1
1067.1
914.1
724.4
943.2
1032.5
1220.7
3347.3

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0861.5871.2838.2
832
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

018123.618844.816420.1
27986
20597.3
17206
7854.6
8588.4
7565.3
5422.3
5448.8
6569.1
5483.6

balance-sheet.row.preferred-stock

0000
52508.7
44066.9
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0393.1393.1393.1
377
377
377
377
377
377
377
377
377
377

balance-sheet.row.retained-earnings

035684.425543.924241
15386.4
12868.7
0
0
0
0
0
0
823
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

0335.418808.818513.8
-4951.5
-3513.8
-2455.4
-4554.4
-3878.2
-3141.9
-2681.2
-2282.6
-1950.9
-1615.5

balance-sheet.row.other-total-stockholders-equity

07291.87629.78128.2
-31126.5
-26610.6
24279.8
23188.5
19506.6
11611.2
9059.9
6935
4700.9
4191.3

balance-sheet.row.total-stockholders-equity

043704.752375.551276.1
32194.1
27188.2
22201.4
19011.1
16005.4
8846.4
6755.7
5029.4
3950
2952.8

balance-sheet.row.total-liabilities-and-stockholders-equity

061828.371220.367089.8
59890.5
47777.6
39410.5
26866.8
24593.8
16411.7
12178
10478.2
10519
8436.5

balance-sheet.row.minority-interest

000-606.4
-289.6
-7.9
3.1
1.1
0
0
0
0
0
0

balance-sheet.row.total-equity

043704.752375.550669.7
31904.5
27180.3
22204.5
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-

Total Investments

0963.31184493.1
176.2
487.6
416.4
1002.2
21.1
22.6
33.6
33
33
32.6

balance-sheet.row.total-debt

07220.27171.15836.1
18306.9
11284.3
7077.8
885.2
1564.2
2635
1094
1867.9
2343.1
3279.1

balance-sheet.row.net-debt

06465.46560.24855.5
17588.5
9293.6
6240.3
-645.6
-2944.1
2366.7
854.4
1706.9
1872.3
3216.2

Rahavoogude aruanne

Alembic Pharmaceuticals Limited finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010

cash-flows.row.net-income

03545.96201.113680.8
9998.2
7493.2
5412.7
5253.6
9356
3590.7
3106.1
2063.5
1609.8
1068.4

cash-flows.row.depreciation-and-amortization

02754.32867.81834.7
1573.2
1152.3
1054.6
829.7
722.1
444.1
404.9
349.7
336.5
295.9

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-575.6-3673.42395.4
-5928.4
1085.2
-1808.5
-1965.3
1345.6
-1625
-720.7
438.6
-626.2
-488.8

cash-flows.row.account-receivables

0-2228.8-4696.25109.3
-3582.6
361.9
0
0
0
0
0
0
0
0

cash-flows.row.inventory

01344.4-1235.5-2986.2
-2202.7
-2333.3
-1011.8
-629.6
-1948.1
-719.9
-439.4
-80.9
-395.1
-62.9

cash-flows.row.account-payables

0-281.7366.7452.7
-211.1
-527.7
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0590.51891.6-180.4
68
3584.3
-796.7
-1335.7
3293.7
-905.1
-281.3
519.5
-231.1
-426

cash-flows.row.other-non-cash-items

01514.9128-3277.1
-1151.7
-1611.1
-1534.6
-1230
-2119.9
-692.2
-428.1
-203.7
87.3
86.3

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-4434.1-4256.4-6595.1
-7349
-7643.7
-8217.5
-4703.8
-3036.2
-2235.8
-819.6
-859.7
-612.6
-625.4

cash-flows.row.acquisitions-net

018.746.1-4.6
6
-143.6
-784.1
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0-70-1392.9-1861
-15.2
-143.6
0
0
-81.3
-341.9
0
0
0
0

cash-flows.row.sales-maturities-of-investments

0-18.71869.71861
9.2
143.6
0
36
0
0
0
0
0
0

cash-flows.row.other-investing-activites

028.213.8-1788.4
32.7
231.3
157.8
206
12.7
21.6
9
189.5
48.7
57.3

cash-flows.row.net-cash-used-for-investing-activites

0-4475.9-3719.7-8388.1
-7316.3
-7556
-8843.8
-4461.8
-3104.8
-2556.1
-810.6
-670.2
-563.9
-568.1

cash-flows.row.debt-repayment

0-2000-3000-3792.7
-2000
-6043.9
0
-381.2
-1264.1
-372
-854.3
-1700.9
-514.4
0

cash-flows.row.common-stock-issued

0007340.8
0
0
0
0
0
0
0
0
0
110

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-1965.6-2751.90
-3259.7
-909.1
-907.6
-901
-652.7
-655
-545.8
-303.6
-216.4
0

cash-flows.row.other-financing-activites

013463578.4-9522.4
6808.2
7543.4
5933.9
-6.5
-42.3
1894.1
-110.5
-283.3
295.2
-591.5

cash-flows.row.net-cash-used-provided-by-financing-activities

0-2619.6-2173.5-5974.3
1548.5
590.4
5026.3
-1288.7
-1959.1
867.2
-1510.6
-2287.8
-435.6
-481.5

cash-flows.row.effect-of-forex-changes-on-cash

000-9.3
4.1
-0.7
-0.1
0.1
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0143.9-369.7262.2
-1272.3
1153.3
-693.4
-2862.4
4240
28.6
41
-309.8
407.9
-87.7

cash-flows.row.cash-at-end-of-period

0754.8610.9980.6
718.4
1990.7
837.4
1530.8
4508.3
268.3
202.1
161.1
470.8
62.9

cash-flows.row.cash-at-beginning-of-period

0610.9980.6718.4
1990.7
837.4
1530.8
4393.2
268.3
239.6
161.1
470.9
62.9
150.6

cash-flows.row.operating-cash-flow

07239.55523.514633.8
4491.3
8119.6
3124.2
2888
9303.9
1717.6
2362.2
2648.2
1407.4
961.8

cash-flows.row.capital-expenditure

0-4434.1-4256.4-6595.1
-7349
-7643.7
-8217.5
-4703.8
-3036.2
-2235.8
-819.6
-859.7
-612.6
-625.4

cash-flows.row.free-cash-flow

02805.41267.18038.7
-2857.7
475.9
-5093.3
-1815.8
6267.8
-518.2
1542.6
1788.4
794.8
336.4

Kasumiaruande rida

Alembic Pharmaceuticals Limited tulud muutusid võrreldes eelmise perioodiga NaN%. APLLTD.NS brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010

income-statement-row.row.total-revenue

056526.252317.952762.2
44919.7
38066.1
30350.4
30300.6
30549.7
20099.7
18201.1
14931.4
14663.9
11989.9

income-statement-row.row.cost-of-revenue

017088.217231.915212.7
13141.1
11933.8
10621.3
10372.7
8425.7
7582.5
7591.5
7166.3
7079.2
6523.6

income-statement-row.row.gross-profit

0394383508637549.5
31778.6
26132.3
19729.1
19927.9
22124.1
12517.2
10609.7
7765.2
7584.7
5466.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

027.41.32
0.2
2.3
0.3
2.5
6737.5
17.3
10
3318
4.4
2551.2

income-statement-row.row.operating-expenses

035108.92916024581.1
20669
18558.1
14630.6
14535.9
12766.6
8985.3
7399.9
5624.9
5651.5
4159

income-statement-row.row.cost-and-expenses

052197.146391.939793.8
33810.1
30491.9
25251.9
24908.6
21192.2
16567.8
14991.4
12791.2
12730.7
10682.6

income-statement-row.row.interest-income

03.317.315.8
17.3
25.8
6.2
9.2
5.9
20.3
5.9
94.1
113.3
0

income-statement-row.row.interest-expense

0501.7177.3160.2
271.6
184.1
34
51.2
42.7
38.1
104
239.8
375.5
238.9

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-831.8379.31029.8
-1115.3
-12.8
314.2
-138.4
-1.5
58.9
-103.7
-76.7
-323.3
-238.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

027.41.32
0.2
2.3
0.3
2.5
6737.5
17.3
10
3318
4.4
2551.2

income-statement-row.row.total-operating-expenses

0-831.8379.31029.8
-1115.3
-12.8
314.2
-138.4
-1.5
58.9
-103.7
-76.7
-323.3
-238.9

income-statement-row.row.interest-expense

0501.7177.3160.2
271.6
184.1
34
51.2
42.7
38.1
104
239.8
375.5
238.9

income-statement-row.row.depreciation-and-amortization

02754.32867.81834.7
1573.2
1152.3
1054.6
829.7
722.1
444.1
404.9
349.7
336.5
295.9

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

04377.85874.712968.4
11114.1
7413.2
5098.5
5392
9357.5
3531.9
3209.8
2140.2
1933.1
1307.3

income-statement-row.row.income-before-tax

03545.96201.113680.8
9998.2
7493.2
5412.7
5253.6
9356
3590.7
3106.1
2063.5
1609.8
1068.4

income-statement-row.row.income-tax-expense

0126.11044.62533.2
1991.8
1567.5
1203.5
1221.9
2160.1
763.5
751
411
308.5
214.6

income-statement-row.row.net-income

03419.95209.411465
8288.2
5843.7
4126.3
4031.7
7194.4
2829.2
2355.1
1652.5
1301.3
853.9

Korduma kippuv küsimus

Mis on Alembic Pharmaceuticals Limited (APLLTD.NS) koguvara?

Alembic Pharmaceuticals Limited (APLLTD.NS) koguvara on 61828300000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.711.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 28.216.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.096.

Mis on ettevõtte kogutulu?

Kogutulu on 0.100.

Mis on Alembic Pharmaceuticals Limited (APLLTD.NS) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 3419900000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 7220200000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 35108900000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 0.000.